Cargando…
Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome
BACKGROUND: It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. METHODS: To investigate its relationship with the outcome of HCV standard combination the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102464/ https://www.ncbi.nlm.nih.gov/pubmed/30174396 http://dx.doi.org/10.20524/aog.2018.0290 |
_version_ | 1783349169139744768 |
---|---|
author | Mylopoulou, Theodora Papadopoulos, Vasileios Kassela, Katerina Karakasiliotis, Ioannis Souvalidou, Fani Mimidis, Panagiotis Veletza, Stavroula Mavromara, Penelope Mimidis, Konstantinos |
author_facet | Mylopoulou, Theodora Papadopoulos, Vasileios Kassela, Katerina Karakasiliotis, Ioannis Souvalidou, Fani Mimidis, Panagiotis Veletza, Stavroula Mavromara, Penelope Mimidis, Konstantinos |
author_sort | Mylopoulou, Theodora |
collection | PubMed |
description | BACKGROUND: It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. METHODS: To investigate its relationship with the outcome of HCV standard combination therapy with peginterferon-α plus ribavirin, we screened 139 consecutive HCV patients (119 with chronic HCV infection and 20 who spontaneously cleared HCV) for the presence of anti-core+1 antibodies (Abs). In addition, liver fibrosis was determined by FibroScan in all but one patients. RESULTS: Twenty-nine patients were cirrhotic (stiffness >12.5 kPa, F4 METAVIR), all of them with mild liver cirrhosis (Child-Pugh score A). Eighty-six of 139 patients were treatment-experienced with standard combination therapy. Fifty of them had achieved a sustained virological response, while 36 were non-responders. The prevalence of anti-core+1 Abs in patients with chronic HCV infection was 22.69% (27/119 patients): 18% (9/50 patients) in responders and 36.11% (13/36 patients) in non-responders (P=0.050). Five (17.24%) of the 29 cirrhotic patients and 22 (24.72%) of the 89 non-cirrhotic patients were positive for anti-core+1 Abs (P=0.405). Furthermore, the presence of anti-core+1 Abs correlated with the poor response interleukin (IL) 28B genotype TT (P=0.040). No correlation between spontaneous clearance and anti-core+1 Abs was observed (P=0.088). CONCLUSION: The presence of anti-core+1 Abs might be correlated with the poor response IL28B TT genotype and may negatively affect the outcome of standard combination treatments in HCV patients, suggesting that core+1 may play a biological role in the course of HCV infection. |
format | Online Article Text |
id | pubmed-6102464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hellenic Society of Gastroenterology |
record_format | MEDLINE/PubMed |
spelling | pubmed-61024642018-09-01 Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome Mylopoulou, Theodora Papadopoulos, Vasileios Kassela, Katerina Karakasiliotis, Ioannis Souvalidou, Fani Mimidis, Panagiotis Veletza, Stavroula Mavromara, Penelope Mimidis, Konstantinos Ann Gastroenterol Original Article BACKGROUND: It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. METHODS: To investigate its relationship with the outcome of HCV standard combination therapy with peginterferon-α plus ribavirin, we screened 139 consecutive HCV patients (119 with chronic HCV infection and 20 who spontaneously cleared HCV) for the presence of anti-core+1 antibodies (Abs). In addition, liver fibrosis was determined by FibroScan in all but one patients. RESULTS: Twenty-nine patients were cirrhotic (stiffness >12.5 kPa, F4 METAVIR), all of them with mild liver cirrhosis (Child-Pugh score A). Eighty-six of 139 patients were treatment-experienced with standard combination therapy. Fifty of them had achieved a sustained virological response, while 36 were non-responders. The prevalence of anti-core+1 Abs in patients with chronic HCV infection was 22.69% (27/119 patients): 18% (9/50 patients) in responders and 36.11% (13/36 patients) in non-responders (P=0.050). Five (17.24%) of the 29 cirrhotic patients and 22 (24.72%) of the 89 non-cirrhotic patients were positive for anti-core+1 Abs (P=0.405). Furthermore, the presence of anti-core+1 Abs correlated with the poor response interleukin (IL) 28B genotype TT (P=0.040). No correlation between spontaneous clearance and anti-core+1 Abs was observed (P=0.088). CONCLUSION: The presence of anti-core+1 Abs might be correlated with the poor response IL28B TT genotype and may negatively affect the outcome of standard combination treatments in HCV patients, suggesting that core+1 may play a biological role in the course of HCV infection. Hellenic Society of Gastroenterology 2018 2018-07-13 /pmc/articles/PMC6102464/ /pubmed/30174396 http://dx.doi.org/10.20524/aog.2018.0290 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Mylopoulou, Theodora Papadopoulos, Vasileios Kassela, Katerina Karakasiliotis, Ioannis Souvalidou, Fani Mimidis, Panagiotis Veletza, Stavroula Mavromara, Penelope Mimidis, Konstantinos Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome |
title | Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome |
title_full | Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome |
title_fullStr | Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome |
title_full_unstemmed | Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome |
title_short | Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome |
title_sort | relationship between antibodies to hepatitis c virus core+1 protein and treatment outcome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102464/ https://www.ncbi.nlm.nih.gov/pubmed/30174396 http://dx.doi.org/10.20524/aog.2018.0290 |
work_keys_str_mv | AT mylopouloutheodora relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome AT papadopoulosvasileios relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome AT kasselakaterina relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome AT karakasiliotisioannis relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome AT souvalidoufani relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome AT mimidispanagiotis relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome AT veletzastavroula relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome AT mavromarapenelope relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome AT mimidiskonstantinos relationshipbetweenantibodiestohepatitiscviruscore1proteinandtreatmentoutcome |